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26 = Number of Cholesterol Treatment Trialists’ (CTT)
11 = Number of Trials in CTTs that are actually PRIMARY 
PREVENTION
3 = Number of CTT’s that show all cause mortality 
REDUCTION
8 = Number of CTT’s that show NO all cause mortality 
reduction
Eight out of eleven studies appears to be a wide margin of 
evidence supporting no effect on all-cause mortality in the 
primary prevention setting, with the use of statins. 
To come to a different conclusion would be to put more 
weight on the three positive studies, which would seem 
unlikely to be true given the evidence 
2013 ACC/AHA Guideline on the Treatment of Blood 
Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in 
Adults – PRIMARY PREVENTION
Does the use of statins, in the primary 
prevention setting, without additional risk 
factors, affect all-cause mortality?
The answer is that a review of the evidence used in the 
2013 ACC/AHA Guideline on the Treatment of Blood 
Cholesterol to Reduce Atherosclerotic Cardiovascular Risk 
in Adults, the Cholesterol Treatment Trialists’ (CTT), 
demonstrates more evidence that not that statin therapy 
does not reduce the risk of all-cause mortality.
JUPITER – “Rosuvastatin also significantly reduced 
the incidence of death from any cause.”
AFCAPS/TexCAPS – “Rates for overall mortality, 
cardiovascular mortality, noncardiovascular mortality, 
and fatal cancer were low, and there were no
treatment group differences.”
CARDS – “We  recorded  a  27%  fall in  all-cause  
mortality  in patients allocated atorvastatin.”
WOSCOPS- “treating 1000 middle-aged … 
pravastatin for five years will result in …2 fewer 
deaths from other causes than would be expected in 
the absence of treatment.”
4D- “Atorvastatin had no significant effect on the 
individual components of the primary end point.”
ALERT- “Total mortality and graft loss did not differ 
significantly between groups.”
ALLHAT-LLT – “All-cause mortality was similar for 
the 2 groups.”
ASCOT-LLA – “All-cause mortality was non-
significantly reduced”
ASPEN – “Composite end point reductions were not 
statistically significant.”
AURORA – “Rosuvastatin had no benefit in any 
subgroup examined, including patients with diabetes”
MEGA – “Although treatment with pravastatin was 
associated with lower total mortality than with diet 
alone, this result was not significant”
Cardiovascular disease would include strokes, myocardial 
infarctions, arrhythmias, peripheral arterial disease, or 
heart valve problems.  
An event from one of these conditions can have a profound 
effect on a patient’s life, but not cause death.  
This is important to remember because the conclusion that 
statins do not reduce all-cause mortality in the primary 
prevention setting does not mean that statins will not 
protect against such cardiovascular events. 
Although patients may end up living about the same amount 
of years, whether they take statins or not, it does not mean 
that they will have a better quality of life during those 
years. 
Where the research from this project can be useful in the 
clinical setting, especially primary care, is when patients 
have difficulty with the side effects of statins
Clinicians should discuss the risks and benefits to statin 
therapy before starting a regiment.  This project will aid in 
that discussion.  
I would like to acknowledge the help of Julie Percival (statistics), Jeremy Hopkin, 
MD (clinical advisor), Douglas Callahan, DO (clinical advisor), Jay Metzger PA-C 
(faculty advisor).  Most of all I would like to acknowledge my wonder wife and 
children for putting up with multiple conversations that I am sure did not interest 
them, and being so understanding for all the time away from them that this project 
took to complete. 
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ALL-CAUSE MORTALITY in PRIMARY PREVENTION
• Without factoring in any other data sets, evidence is 
controversial.
• By only focusing on one specific factor, the hope is to 
paint a clear picture of that factor, thereby facilitating a 
better decision making process. 
• All-cause mortality is one of the end points that is most 
easily tracked without interruption needed.  
During routine yearly physicals, primary care providers often 
evaluate serum laboratory lipid levels.  Many of these 
patients have no past medical history of cardiovascular 
events related to atherosclerotic disease.  Some patients do 
not have secondary risk factors, such as diabetes mellitus or 
smoking history.  
Previous cardiovascular events provide stronger indications for 
the use of HMG-CoA reductase inhibitors (statins).  In the 
absence of these, the provider may turn to current 
guidelines, in this case the 2013 the American College of 
Cardiology and the American Heart Association published 
the 2013 ACC/AHA Guideline on the Treatment of Blood 
Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in 
Adults.  
There is however, controversy, even within the evidence to 
this guideline, about the effect of statins in primary 
prevention with respect to the reduction that they have on 
all-cause mortality.  There are many factors that could 
influence the use of statin therapy for primary prevention.  
These could include non-fatal myocardial infarction, non-
fatal cerebral vascular accident, among others.  One of the 
biggest factors is all-cause mortality. 
A review of the evidence cited for these guidelines 
demonstrates that the majority of the clinical trials did not 
show a reduction in all-cause mortality, in primary 
prevention.  It is important to understand that this evidence 
comes directly from the same evidence that the ACC/AHA 
used to create the primary prevention guidelines. 
